Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Post by C10H12N2on Feb 01, 2023 6:36pm
181 Views
Post# 35260934

The CEO Wants You To Believe It's Current Market Conditions.

The CEO Wants You To Believe It's Current Market Conditions.

The CEO claims all your woes are because Penny Stock Investors @ CSE & OTC are stupid people. The CEO has stated the same thing in the recent past then retracted. Says he was misunderstood. Yet, he repeated it again. Hence, the mangled mumbo jumbo mantra about existing shareholders not understanding the value of the company. More specifically, not understanding their perceived 20M U$ valuation of the Phase 1 DMT angle that was decoupled from your narrative. Yeah, the CEO is out and about spouting to the rooftops about DMT.

 
Meanwhile, you're the ones stuck paying the bills for that ineffective mess/aging as Algernon Neuroscience sits back and watches you spend your way to another fire sale to raise a few pennies from pennyland pirates as usual. You continue to get played like all day suckers 24/7/365. Maybe the dumb-dumb excuse the CEO has leveled against shareholders does have some merit. However, this is his direct leadership since 2018:
 
The Long Descent Into Dante's Inferno


<< Previous
Bullboard Posts
Next >>